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The effect of i.v. sumatriptan, a selective 5-HT1-receptor agonist on central haemodynamics and the coronary circulation. Br J Clin Pharmacol 1992;34:541-546. 25. Golino P, Piscione F, Willerson JT, et al Cardiol 1994; 74:363-368. 1994; 344:985-986. HLA DR15 (DR2) and DQB1*0602 typing studies in 188 narcoleptic patients with cataplexy A.E. Rogers, PhD, RN; J. Meehan, BS; C . Guilleminault, MD; F.C. Grumet, MD; and E. Mignot, MD Article abstract-Narcolepsy is considered a homogeneous clinical entity when excessive daytime sleepiness and cataplexy are present. Cataplexy is a polymorphic symptom that can be very mild and is thus subjectively defined. The Multiple Sleep Latency Test (MSLT) is widely used as a diagnostic test for narcolepsy. A short mean sleep latency and multiple sleep onset REM periods (SOREMPs) are typically observed in narcoleptic patients. The discovery of a tight association of narcolepsy with HLA class I1 antigens offers a unique opportunity to explore the respective value of the MSLT or of the presence of clear-cut cataplexy in defining an etiologically homogeneous group of narcoleptic patients. In this study, we carried out HLA typing for DR15(DR2) and DQBl"0602 in 188 narcoleptic patients with cataplexy in three ethnic groups (24 Asians, 61 Blacks, and 103 Caucasians). These results confirm the importance of DQBl"0602 typing rather than DR15 (DR2) typing in Black narcoleptic patients and demonstrate that the presence of clear-cut cataplexy is a better predictor for DQBl"0602 positivity than the presence of abnormal MSLT results. NEUROLOGY 1997; 48:1550 -1556 Narcolepsy is a disorder characterized by excessive daytime sleepiness, sudden losses of voluntary muscle tone in response to strong emotion ( association (100%) between human leukocyte antigen (HLA) DR2 and narcolepsy among Japanese patients. These findings were quickly confirmed in Caucasian populations in A u~t r a l i a ,~ Europe,8-10 and North America.ll In these populations, DR2 frequency ranges from 20 to 30% but almost all narcoleptic patients tested were DR2 positive. Some of these earliest reports, which focused on DR2, also mentioned that the frequency of second antigen, HLA-DQ1, was significantly higher in narcoleptic patients than in normal Japanese and Caucasian control ~u b j e c t s .~,~J~J~ The high frequency of DQ1 in control subjects, 60 to SO%, however, greatly diminished the specificity of DQ1 as a marker for narcolepsy.
The discovery of several cases of DR2-negative narc01epsy~~-~6 during the mid-1980s triggered a flurry of questions. For example, did these patients really have narcolepsy or could these DR2-negative cases be attributed to differences in the criteria used to diagnose nar~olepsy?'~J* Or, could there be ethnic differences in linkage disequilibrium between DR2 and a putative narcolepsy-susceptibility gene?15J6 In one of these early reports, Neely et a1.16 only included Black narcoleptic patients and 67% were DR2 positive. Although Nezu et al.19 described one Japanese non-DR2 case where the diagnosis of narcolepsy was quite questionable, other DR2-negative patients, mostly Caucasians, had a substantial history that was supportive of the diagnosis of narcolepsycataplexy. 13-16 In 1987, Matsuki et al.17 reported that DR2 frequencies varied between 92 and 100% depending on the criteria used for diagnosis of narcolepsy (e.g., excessive daily sleepiness [EDSI present for more than 6 months, EDS with cataplexy, EDS with cataplexy plus two sleep-onset REM periods). The conclusion of the Japanese group, based on a large sample of Japanese patients (n = 2271, was that presence of cataplexy was the best determinant for DR2 positivity, and that earlier reports on non-DR2 narcoleptic patients were likely the result of differences in diagnostic approaches. This position can be best exemplified as in Honda and Matsuki, 20 "Most of the reports on DR2-negative narcolepsy lack precise clinical definition of cataplexy, and therefore might have included nonnarcoleptic patients owing to a difference in clinical judgment."
Since these earlier reports, HLA class I1 typing techniques have become increasingly sophisticated.21 This first led to the subtyping of DR2 into DR15 and DR16 subtypes, with all narcoleptic patients found to be DR15-positive. As DR15 is the most common subtype of DR2 in most ethnic groups, this serologic splitting of DR2 did not improve the value of HLA typing for diagnostic purposes. More recently, subtyping was made possible at the genomic level, thus leading to the identification of more than 15 subtypes of DR2 and 30 subtypes of DQLZ1 Among those subtypes, DRB1*1501 (DR2) together with DQB1*0602 (DQ1) were identified in all Caucasian and Japanese narcoleptic patients with DR2, DQl.22-24 In black Americans, genomic typing in 28 patients with cataplexy and abnormal Multiple Sleep Latency Test (MSLT) revealed the presence of DRBl"1501 in only three with many patients carrying a new variant of DR15 called DRB1*1503 (19 subjects) and all but one subject being positive for DQB1"0602.24 DQBl"0602 is thus now considered as the best HLA marker across all ethnic groups and this result likely explains the substantially lower DR2 frequency previously reported in black Americans.16
Most of the known HLA DR-or DQ-associated disorders (e.g., multiple sclerosis, insulin-dependent diabetes mellitus) are autoimmune in nature and several investigators have suggested a similar pathologic mechanism for n a r c o l e p~y .~~-~~ To date, however, there is no evidence for a direct involvement of the immune system in this sleep disorder.27 Human narcolepsy is not associated with any detectable circulating autoantibodies, CSF oligoclonal bands, increased sedimentation rate, C-reactive protein at the onset of the disease, or changes in CD4/CD8 lymphocytes subsets usually found in other autoimmune d i~o r d e r s .~~-~~ Pathologic studies have also shown that the CNS of human patients with narcolepsy does not contain sites of lymphocytic infiltration^.^^ HLA DR15 or DQBl"0602 may thus be only linkage markers and not the actual susceptibility genes for n a r c o l e p~y .~~~~~,~~ Recent studies do not, however, favor the linkage marker hypothesis. First, the onset of narcolepsy is associated with increased microglial class I1 expression in a canine model of the disorder.33 Second, detailed HLA haplotyping studies in human narcoleptic patients indicate that susceptibility to narcolepsy narrowly maps to the coding region of the DQBl"0602 and associated DQAl"0102 genes and not in the region flanking these allele^.^^^^^ These results suggest that the HLA DQ molecules themselves are involved in disease predisposition.
Whether or not narcolepsy is autoimmune, DQBl"0602 is neither necessary nor sufficient for the development of the disorder. This DQBl allele is present in 12 to 38% of the general population in various ethnic group^,^^-^^ with only 0.02 to 0.16% affected with narcolepsy-~ataplexy.~~ DQB1*0602 sequence is identical in control and narcoleptic subj e c t~.~~,~~,~~,~~ A few patients with typical narcolepsycataplexy are negative for DQB 1*060234335r39 and family members frequently share the same HLA haplotype with the proband and never develop narcolepsy.10J2,20 Even monozygotic twins can be discordant for the development of narcolepsy; only 25 to 31% of the monozygotic twins reported to date are concordant for n a r c 0 1 e p s y .~~~~~ Overall, the data suggest that narcolepsy-cataplexy, like many other HLA-associated disorders, is a complex disorder that involves both genetic predisposition and environmental triggering factors.
Increasingly sophisticated techniques are being developed for identifying the genetic causes of disease, but without careful subject selection, valuable In this study, we HLA-typed narcoleptic patients with cataplexy in three ethnic groups. Patients were stratified by gender, ethnicity, presence of clear-cut cataplexy (brief episodes of weakness 'in the knees, jaw, face, or neck triggered by laughter, amusement, happiness, game playing, or anger) versus atypical or extremely mild cataplexy (doubtful cataplexy) and abnormal versus atypical MSLT. Our aim was to study the respective value of abnormal MSLT results and of clear-cut cataplexy for defining a homogeneous group of patients displaying the highest possible HLA association.
Methods. Subjects. A total of 188 subjects was obtained from a database of 777 narcoleptic subjects and relatives whose HLA typing has been done at Stanford University. Subjects in the database were recruited using six possible protocols: (1) "random" narcoleptic patients 1663 NEUROLOGY 48 June 1997 from various ethnic groups (n = 291); these subjects were referred to the center because they had narcolepsycataplexy or were diagnosed at the Stanford Sleep Disorder Clinic; (2) parents or relatives of random narcoleptic patients for haplotype relative risk studies or HLA haplotype segregation analysis (n = 93 relatives); (3) relatives and narcoleptic patients of multiplex families (n = 342 subjects in 48 fa mi lie^)^^.^^; (4) narcoleptic subjects recruited because they were found to be non-DR2 positive at another sleep center (n = 41)34,355; (5) subjects and parents with essential hypersomnia (n = 4); (6) posttraumatic narcolepsy cases (n = 6).
In this study, only available "random" narcoleptic subjects with a complete clinical file and an established diagnosis of narcolepsy-cataplexy were included in the analysis. Subjects recruited because of DR2 negativity, posttraumatic narcolepsy, or as part of recruitment effort aiming a t gathering multiplex family study were thus not included in the analysis. A clinical file was established for every subject. The file contained photocopies of clinical notes obtained from the medical file(s) of the patient, notes made by direct interview of the patient by the Center For Narcolepsy staff (mostly by phone), and results of polygraphic studies (e.g., MSLT and nocturnal polysomnography), if any. The Stanford Center for Narcolepsy Sleep Inventory, a 146-item questionnaire requesting details and specific examples for all narcolepsy symptoms experienced, with special emphasis on cataplexy, was also completed and included in the file (108 of 188 patients). Final diagnosiskategorization was made by one of us (C.G.) after a review of the clinical data file and without any knowledge of the HLA testing, name of the patient, or the patient's geographic origin. Table 1 shows how subjects were categorized based on their clinical history and polysomnographic studies.
Ninety-four of the 291 "random" subjects were excluded either because the patient's diagnosis of narcolepsycataplexy could not be confirmed or because the clinical file was not complete at the time of the submission of this manuscript. Subjects reporting a mixed ethnic background, e.g., Asian-Caucasian, black-Caucasian were also excluded due to their small number (n = 9). Our final sample included 107 females and 80 males (1 unknown) recruited from Asia (n = 141, Europe (n = 31, and North America ( n = 171). Twenty-four subjects (12.8%) were Asian, 61 (32.4%) were black, and 103 (54.8%) were Caucasian. Four (2.1%) of the 188 subjects recruited as "random" narcoleptic patients were later found to have another family member with documented narcolepsy-cataplexy. The presence or absence of DQB14'0602 and DRB1*15 was determined either using polymerase chain reaction sequence specific oligonucleotide (PCR-SSO) as previously describedZ4.,'l9 or using Innotype reverse dot blot kits according to manufacturer recommendation (Robbins Scientific, Sunnyvale, CAI. All non-DR15 and/or non-DQB1*0602-positive subjects were fully HLA DR and DQ high resolution PCR SSO typed as described in Kimura et al.45 to confirm the presence or absence of DR15 and DQB1*0602.
Subject categorizations. Group assignments (A-G) were then used to categorize subjects by their history of cataplexy and MSLT results. Subject,s who reported recurrent brief episodes of weakness in the knees, jaw, face, or neck triggered by laughter, amusement, happiness, game playing, or anger were considered to have clear-cut history of cataplexy (Groups A-F). Subjects who reported atypical symptoms (e.g., unilateral weakness in one arm or cataplexy mostly induced by stress or by other less typical emotions, unusually long episodes, etc.) or extremely mild symptoms (e.g., feeling of weakness that does not result in detectable changes in body position or report of a single or a few attacks in the past) were considered to have a "possible" history of cataplexy (Group G).
MSLT data were then analyzed on all subjects. When subjects had a mean sleep latency of 5 8 minutes and a t least two sleep onset REM periods (SOREMPs) their MSLT findings were considered positive (Groups A, G1, G2). Polygraphic results were considered ambiguous when the mean sleep latency was either >8 minutes, or when there were less than two SOREMPs during the MSLT H L A typing. (Groups B, D, G3) or when polygraphic tests other than MSLTs were performed and suggested a possible abnormality (Group C). A third category, no sleep studies performed, was created for subjects who had well-documented history of EDS and clear-cut cataplexy but who had never undergone any diagnostic studies (Group F). Ethnicity and gender were determined from information provided by the subjects. Four variables were used to describe the population: gender, ethnicity (Asian, black, Caucasian), history of cataplexy (clear-cut, atypicaYdoubtful), and MSLT findings (abnormal, ambiguous, not performed). These variables were examined singly and in combination both for descriptive purposes and to evaluate their interrelationships. First, each variable was examined for its relationship with being positive for DRB1*15, and only those variables with a p value of less than 0.10 were included in the multiple logistic regression modeling. Tests of association between each categorical predictor variable and DRB1* 15 positivity were based on chi-square tests. Variables deemed to be significant, statistically and/or medically, were included in final model. The association between being positive for DQB1*0602 and the predictor variables gender, ethnicity, history of cataplexy, and MSLT results was tested in the same way.
Statistical analysis.
Results, DRB1*15 as a marker for narcolepsy. Of the total sample, 19.7% (n = 37) of the subjects were negative for DR15 (DR2), and 80.3% (n = 151) of the subjects were positive. Univariate testing revealed that being positive for DR15 was not associated with gender or MSLT results (table 2) . Therefore, only two covariates (history of cataplexy and ethnicity) were included in the final models tested (table 3) . Two indicator variables were used to analyze the effect of ethnicity; Caucasian, which refers to a comparison of Caucasian and black subjects, and Asian, which compares Asian and black subjects. Additional statistical testing revealed that blacks were significantly dif- ? Asians compared with blacks.
ferent from Asians (x2 = 7.584, p = 0.005) and Caucasians (x2 = 6.656, p = 0.009), but there was no significant difference in Asians and Caucasians (x2 = 2.169, p = 0.140).
Although the first model tested (DRB1*15 #1, see table 31, using cataplexy alone, was significant ( p = 0.007, and p = 0.0031, it was neither sensitive nor specific. When cataplexy and ethnicity were combined in the second model (DRBl"15 #2, see table 3) , both sensitivity and specificity were improved. Subjects with atypicaVdoubtfu1 cataplexy were 3.9 times more likely than subjects with clear-cut cataplexy to be DR15-negative in this model. Black patients are 2.5 and 9.4 times more likely than Asian or Caucasian patients to be DR15-negative in this model. Most subjects were positive for DQB1*0602 (n = 162, 87.6%), only 23 subjects were negative (15 of whom had 146-item narcolepsy sleep inventory completed on file). Although it appeared that more Asians (91.3%) were positive than blacks (88.5%) and Caucasians (86.1%), these differences were not statistically significant (x2 = 0.536, p = 0.765). Since chisquare testing revealed that ethnicity, gender, and MSLT results were not associated with being positive for DQB1*0602 (see table 21, only a history of cataplexy was included in the logistic regression model (see table 3 ). Although this model was highly significant ( p = 0.0026, and p = 0.0003), it is not particularly sensitive or specific. The addition of other covariates, e.g., ethnicity or MSLT results, did not improve the sensitivity or specificity of the model. Subjects with doubtfullatypical cataplexy were 6.8 times more likely than subjects with clear-cut cataplexy to be DQB1*0602 negative in this model.
DQB1*0602 as a marker for narcolepsy.
Discussion. Our finding that ethnicity influences the frequency of DRBl"15 among narcoleptic patients confirms previous s t u d i e~l~,~~ that used much smaller sample sizes. Only 41 of our 61 (67.2%) black narcoleptic subjects were positive for this marker, compared with 84.5% (n = 87) of our Caucasian subjects and 95.8% (n = 23) of our Asian subjects (see table 2 ). In contrast, DQBl"0602 positivity was roughly equivalent in all ethnic groups, with values ranging from 86.1 to 91.3% (table 2). Typing for DQBl"0602, rather than for DRBl"15, thus increased diagnostic specificity in blacks but has little or no influence in Asians or Caucasians. In this last ethnic group, however, a recent study34,35 has shown that a small but significant portion (10%) of non-DR15 patients may carry rare DQBl"0602-positive haplotypes without DR15. Typing for DQB1*0602 should thus ideally be performed in all patients instead of typing for DR2 or DR15.
Although the percentage of blacks and Asians positive for these markers is similar t o those reported in earlier ~t~d i e~,~~z~~-~~ the percentage of Caucasian subjects positive for either DR15 (DR2) or DQBl"0602 is slightly lower than usually reported (i.e., 91-100%'0). [6] [7] [8] [9] [10] [11] [12] 22, 24 We are aware of only two other studies reporting such a low percentage of Caucasian subjects with cataplexy who are positive for DRB1*15.23,46 The method of diagnosis and recruitment used in our study may explain the relatively lower HLA association observed. First, we included all our patients without any prior knowledge of HLA typing results. In many other studies, diagnosis was not performed blind of HLA typing results and we believe this is likely to have a significant influence, especially in the context of the 100% association initially reported in Japan. Second, we included patients based on the report of "cataplexy" by a referring clinician and not by direct clinical interviews, and some of these patients had questionable or atypical cataplexy (Category G, doubtful cataplexy in table 1) after review of their clinical files at Stanford University.
In favor of this last hypothesis, the presence of "clear-cut" versus "possible" cataplexy was identified as a critical factor in predicting both DR15 and DQBl"0602 positivity. This contrasted with the poor predictive value of the MSLT findings in this group of patients with cataplexy (see table 2 ). Significantly more subjects with clear-cut cataplexy were positive for DRB1*15 than subjects whose symptoms were considered atypical or possible cataplexy (82.3% versus 50.0%, x2 = 8.80, p = 0.003). Only 57.1% of subjects with possible cataplexy were positive for DQBl"0602 compared with 90.1% of those with clear-cut cataplexy. Cataplexy was a significant covariate in both models. Patients with history of cataplexy were more likely to be positive for DR15 and DQBl"O602 than patients with a possible history of cataplexy. Clearly clinically defining cataplexy might thus be more important than the MSLT for the diagnosis of narcolepsy.
Even in patients with clear-cut cataplexy, HLA DQBl"0602 is neither sufficient nor necessary for the diagnosis of narcolepsy. Approximately 10% of patients with definite cataplexy (with or without MSLT findings) were DQBl"0602 negative in this large series. Genetic epidemiologic data also suggest that HLA-related genetic factors constitute only a small fraction of genetic predisposition to narcolepsy. Twelve to thirty-eight percent of the normal general population in various ethnic groups carry the HLA DQBl"0602 a11ele22-24 and only 0.02 to 0.06% of the population has narcolepsy-~ataplexy.~~ The gene has been sequenced in many control and narcoleptic subjects and found to be normal in all cases.24.35~3s Even if DQBl"0602 is the actual HLA narcolepsy susceptibility gene, it is thus a very low penetrance factor since more than 99.9% of individuals with the gene do not have narcolepsy. Family and twin studies also suggest the importance of environmental and non HLA genetic f a~t o r~.~~,~~.~~~~~ In spite of these limitations, HLA typing can be a useful diagnostic tool, especially in cases where cataplexy is doubtful, atypical, or not present. Samples described in the literature contain varying portions of "narcoleptic" subjects without cataplexy (8-42%b),16.17.20,46,4R suggesting that this less-studied clinical subgroup might actually represent a substantial number of patients. The absence of DQBl"O602 in subjects without or with atypical cataplexy should lead the clinician to explore more thoroughly other possible causes for excessive daytime sleepiness (e.g., abnormal breathing or movements during sleep) and this may have therapeutic consequences. MSLT testing might also be more useful in this group of patients with "possible narcolepsyD than in patients with cataplexy. In our study, of the 157 patients with clear-cut cataplexy who had undergone an MSLT, only 132 (84%) had typical MSLT results (sleep latency 5 8 min and 2 2 SOREMPs). Thus, many genuinely narcoleptic patients would be excluded if positive MSLT findings were required for the diagnosis. In contrast, MSLT can be very useful to demonstrate sleepiness in patients with ill-defined fatigue, tiredness, or sleepiness, with or without sleep paralysis or other symptoms of abnormal REM sleep.
